Market Research Logo

Conference Documentation: Advances and Progress in Drug Design

Conference Documentation: Advances and Progress in Drug Design

SMi are proud to present the 14th Annual Advances and Progress in Drug Design Conference, convening in Central London on Monday 16 and Tuesday 17 February 2015.

The drug is most commonly an organic small molecule that activates or inhibits the function of a biomolecule such as a protein, which in turn results in a therapeutic benefit to the patient. Drug design involves the designing of small molecules that are complementary in shape and charge to the biomolecular target with which they interact and therefore will bind to it. Drug design, is the inventive process of finding new medications based on the knowledge of the biological target.

As science and technology is advancing, drug designing has moved from traditional methods to advanced methods like computer aided drug designing and computational techniques. This informative event will focus on the recent developments and growth drivers in drug design.

High profile scientists from pharma companies and biotech organisations will be speaking about structure based drug designing, fragment based drug designing, computer based drug designing, pharmacokinetics, polypharmacology and metabolism in drug designing.


Day 1
8:30
Registration & Coffee
9:00
Chairman's Opening Remarks
Hugo Gutierrez de Teran, Senior Researcher, Division of Computational and Systems Biology, Uppsala University
9:10
Compound Design and Analysis Using Integrated Chemical and Biological Information
Andreas Bender, Lecturer for Molecular Informatics, University of Cambridge
9:50
Structure based design of PDE2 inhibitors
Gary Tresadern, Principal Scientist-Computational Chemistry, Janssen Research & Development
10:30
Morning Coffee
11:00
Creating Focused Mutant Libraries for Protein Engineering
Paul Labute, President & CEO, Chemical Computing Group
11:40
Application of computational structural biology tools in biotherapeutics discovery
Sudharsan Sridharan, Scientist, MedImmune Inc.
12:20
Networking Lunch
13:20
The ABC of kinase conformations – Interplay of conformation, sequence and ligand binding
Henrik Moebitz, Investigator, Novartis
14:00
Predicting protein structure, ligand binding and receptor selectivity on GPCRs
Hugo Gutierrez de Teran, Senior Researcher, Division of Computational and Systems Biology, Uppsala University
14:40
Afternoon Tea
15:10
Identification of drug candidates using network pharmacology based computational modelling
Ben Allen, Computational Research Scientist, e-Therapeutics plc
15:50
Panel Discussion: How have computational and predictive tools matured for the application of drug discovery?
Hugo Gutierrez de Teran, Senior Researcher, Division of Computational and Systems Biology, Uppsala University
15:50
Panel Discussion: How have computational and predictive tools matured for the application of drug discovery?
Gary Tresadern, Principal Scientist-Computational Chemistry, Janssen Research & Development
15:50
Panel Discussion: How have computational and predictive tools matured for the application of drug discovery?
Paul Labute, President & CEO, Chemical Computing Group
16:30
Chairman’s Closing Remarks and Close of Day One
16:45
Onwards- Drinks Reception by Chemical Computing Group
Day 2
8:30
Registration & Coffee
9:00
Chairman's Opening Remarks
Andreas Bender, Lecturer for Molecular Informatics, University of Cambridge
9:10
Rational GPCR drug discovery?
Zara Sands, Principal Scientist, Medicinal Chemistry, UCB BioPharma
9:50
Fragment Based Design of Protein-Protein Interaction Antagonists
Gianni Chessari, Director, Computational Chemistry, Astex Pharmaceuticals
10:30
Morning Coffee Sponsor Session
11:00
KEYNOTE ADDRESS - Building a Robust Technology Pipeline for Robust Fragment Based Drug Discovery
Gregg Siegal, Chief Scientific Officer, ZoBio BV
11:40
NMR-based fragment screening and validation for novel kinase and phosphate targets
Michael Overduin, Professor of Structural Biology, University of Birmingham
12:20
Networking Lunch
13:20
CASE STUDY: Using X-ray structures on the design of MK2 kinase inhibitors
Arthur Oubrie , Cheif Scientific Officer, Lead Pharma
14:00
High End GPCR Design: The slippery slope to potency, selectivity and kinetics
Francesca Deflorian, Senior Computational Chemist, Heptares Therapeutics
14:40
Afternoon Tea
15:10
Structure-based design of kinase inhibitors
Oliver Plettenburg, Head of Biosensors & Chemical Probes, Sanofi-Aventis
15:50
Using Chemical and Biological information for Compound Selection and Prioritisation
Richard Lewis, Executive Director, Computer-Aided Drug Design, Novartis Pharmaceuticals
16:30
Chairman’s Closing Remarks and Close of Day Two

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report